Literature DB >> 18287288

Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades.

Michelle Darrieux1, Adriana T Moreno1, Daniela M Ferreira1, Fabiana C Pimenta2, Ana Lúcia S S de Andrade2, Alexandre P Y Lopes1, Luciana C C Leite1, Eliane N Miyaji1.   

Abstract

Pneumococcal surface protein A (PspA) is an important vaccine candidate against pneumococcal infections, capable of inducing protection in different animal models. Based on its structural diversity, it has been suggested that a PspA-based vaccine should contain at least one fragment from each of the two major families (family 1, comprising clades 1 and 2, and family 2, comprising clades 3, 4 and 5) in order to elicit broad protection. This study analysed the recognition of a panel of 35 pneumococcal isolates bearing different PspAs by antisera raised against the N-terminal regions of PspA clades 1 to 5. The antiserum to PspA clade 4 was found to show the broadest cross-reactivity, being able to recognize pneumococcal strains containing PspAs of all clades in both families. The cross-reactivity of antibodies elicited against a PspA hybrid including the N-terminal region of clade 1 fused to a shorter and more divergent fragment (clade-defining region, or CDR) of clade 4 (PspA1-4) was also tested, and revealed a strong recognition of isolates containing clades 1, 4 and 5, and weaker reactions with clades 2 and 3. The analysis of serum reactivity against different PspA regions further revealed that the complete N-terminal region rather than just the CDR should be included in an anti-pneumococcal vaccine. A PspA-based vaccine is thus proposed to be composed of the whole N-terminal region of clades 1 and 4, which could also be expressed as a hybrid protein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18287288     DOI: 10.1099/jmm.0.47661-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  27 in total

1.  Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.

Authors:  Míriam A da Silva; Thiago R Converso; Viviane M Gonçalves; Luciana C C Leite; Martha M Tanizaki; Giovana C Barazzone
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

2.  Diversity of pneumococcal surface protein A (PspA) and relation to sequence typing in Streptococcus pneumoniae causing invasive disease in Chinese children.

Authors:  J Qian; K Yao; L Xue; G Xie; Y Zheng; C Wang; Y Shang; H Wang; L Wan; L Liu; C Li; W Ji; Y Wang; P Xu; S Yu; Y-W Tang; Y Yang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-06-04       Impact factor: 3.267

3.  A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains.

Authors:  Jinfei Yu; Xiaorui Chen; Bo Li; Tiejun Gu; Xiangyu Meng; Wei Kong; Yongge Wu
Journal:  Immunol Res       Date:  2018-08       Impact factor: 2.829

4.  Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection.

Authors:  Adriana T Moreno; Maria Leonor S Oliveira; Daniela M Ferreira; Paulo L Ho; Michelle Darrieux; Luciana C C Leite; Jorge M C Ferreira; Fabiana C Pimenta; Ana Lúcia S S Andrade; Eliane N Miyaji
Journal:  Clin Vaccine Immunol       Date:  2010-01-20

5.  Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.

Authors:  Carolina Salcedo-Rivillas; Anne-Sophie Debrie; Eliane Namie Miyaji; Jorge M C Ferreira; Isaías Raw; Camille Locht; Paulo L Ho; Nathalie Mielcarek; Maria Leonor S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2014-05-07

Review 6.  Panel 6: Vaccines.

Authors:  Stephen I Pelton; Melinda M Pettigrew; Stephen J Barenkamp; Fabrice Godfroid; Carlos G Grijalva; Amanda Leach; Janak Patel; Timothy F Murphy; Sanja Selak; Lauren O Bakaletz
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

7.  Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice.

Authors:  Maria Leonor S Oliveira; Eliane N Miyaji; Daniela M Ferreira; Adriana T Moreno; Patricia C D Ferreira; Fernanda A Lima; Fernanda L Santos; Maria Aparecida Sakauchi; Célia S Takata; Hisako G Higashi; Isaías Raw; Flavia S Kubrusly; Paulo L Ho
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

8.  Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice.

Authors:  D M Ferreira; M Darrieux; D A Silva; L C C Leite; J M C Ferreira; P L Ho; E N Miyaji; M L S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2009-03-11

9.  Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine.

Authors:  Reshmi Mukerji; Shaper Mirza; Aoife M Roche; Rebecca W Widener; Christina M Croney; Dong-Kwon Rhee; Jeffrey N Weiser; Alexander J Szalai; David E Briles
Journal:  J Immunol       Date:  2012-10-26       Impact factor: 5.422

10.  Conjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune response.

Authors:  Catia T Perciani; Giovana C Barazzone; Cibelly Goulart; Eneas Carvalho; Joaquin Cabrera-Crespo; Viviane M Gonçalves; Luciana C C Leite; Martha M Tanizaki
Journal:  Clin Vaccine Immunol       Date:  2013-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.